Abstract: A process is described to purify collagen fibers while allowing the individual constituent molecules to retain their native configuration and 3-dimensional arrangement characteristic of the tissues from which they are derived. Collagenous tissues used as sources of purified collagen and for manufacturing bioprosthesis contain significant amounts of other substances (elastin, glycoproteins, polysaccharides, cell derived materials, etc.). This process becomes therefore useful to selectively preserve the collagen in its native conformation and to eliminate contaminants. The method described allows for enzymatic removal of all extraneous materials while preserving the native collagen molecules in their original fiber configuration.

Abstract: The present invention relates to fluorochemical blood substitutes used for preserving mammalian tissue having lysophosphatidyl compounds in non-toxic concentrations. More specifically, the invention relates to aqueous fluorochemical emulsions of a fluorochemical and an emulsifier useful as oxygen delivery agents and methods of preserving tissue in investigational and clinical settings, particularly those settings involving in in vivo transfusion, cardiac and other organ preservation, and in vitro organ perfusion.

Abstract: In the method for purifying factor VIII from cryoprecipitate, which is dissolved and then treated with alumina gel, the extract is diluted to a protein concentration not exceeding approximately 5 g/l and subjected to viral inactivation with solvent/detergent, the inactivated extract containing the solvent/detergent is then subjected to chromatography on a weak anion exchange column which is hydrophilic in nature and factor VIII is then eluted with a dissociating buffer.

Abstract: The present invention relates, in general, to oncoimmunins. In particular, the present invention relates to oncoimmunin-lymphoid factor and oncoimmunin-myeloid factor, pharmaceutical compositions of said factors, and methods of use of said factors.

Abstract: An imidoester, cross-linked hemoglobin composition useful in the transport of oxygen to living cells and being essentially free of any impurities, a P50 of at least 13 mm Hg and predominantly in tetramer form. Preferably, the cross-linked hemoglobin composition has a predominant molecular weight of at least 64,000. The purified and cross-linked hemoglobin has improved cross-link stability to autoxidation and can be used as a blood substitute for mammals or as an oxygen transport fluid.

Abstract: Highly purified antihemophilic factor is produced by a process comprising a PEG precipitation step, a gel filtration step and a virus inactivation step. Al(OH).sub.3 adsorption and PEG precipitation carried out at room temperature allow processing to proceed directly to a gel filtration step.

Abstract: A method of terminating pregnancy in mammals is described by a novel application of the common fertility-promoting hormone known as human menopausal gonadotropin. A single injection of this gonadotropic hormone as early as the first day of conception can terminate pregnancy.

Abstract: The invention is directed to a stroma-free tetrameric mammalian hemoglobin which is crosslinked with benzenepentacarboxylate, in which the crosslinking is carried out by a method comprising the step of activating at least two carboxylate groups of the benzenepentacarboxylate with an activating agent prior to reaction with the hemoglobin as well as methods for its production. Crosslinked stroma-free hemoglobin produced by methods of the present invention may be used in applications requiring physiological oxygen carriers such as in blood substitute solutions, or as in a plasma expander.

Abstract: A method of sorting living cells based on DNA content. Mammalian sperm subpopulations enriched in X- or Y-sperm. X- and Y-enriched sperm-plasma-membrane vesicles. Substantially pure sex-associated membrane (SAM) proteins. Antibodies binding to X-or Y-SAM proteins, essentially free of antibodies binding to Y- or X-SAM proteins respectively, or to the H-Y antigen. Semen samples enriched for X- or Y-sperm. Methods for increasing the probability that offspring will be male or female comprising the step of allowing as penn from an enriched semen sample to fertilize an ovum. Methods for increasing the probability that offspring will be male or female comprising the step of immunizing a female with X- or Y-SAM proteins. Methods of decreasing fertility comprising the step of immunizing a female with both X- and Y-sperm. Methods of increasing the probability that mammalian offspring will carry a gene for a particular sex-chromosome linked trait.

Abstract: A process for producing regenerated collagen fiber from solubilized collagen including adjusting a degree of swelling of solubilized collagen to 100 to 300% and then treating the resulting solubilized collagen with an aqueous solution of a metallic salt. The regenerated collagen fiber has excellent water resistance and undergoes no waving on contact with water.

Abstract: The invention relates to a process for the manufacture of a high-purity activated factor VII concentrate.This process comprises the use of a plasma free of cryoprecipitate, preferably of human origin, as well as at least one purification step involving chromatography at least once on an ion exchange resin, and a factor VII activation step, wherein the first stage is direct activation of the factor VII in the crude supernatant of plasma free of cryoprecipitate, without the addition of exogenous proteins.By virtue of the invention, the high-purity activated factor VII is essentially free of vitamin K-dependent factors and factors VIIIC and VIIICAg and has a factor VIIa/factor VII ratio greater than 5 with a specific activity of the activated factor VII greater than 200 IU/mg of proteins.

Abstract: The invention is directed to a low oxygen affinity stroma-free tetrameric mammalian hemoglobin which is produced by crosslinkng with a derivative of benzenetricarboxylate, as well as methods for its preparation. Crosslinked stroma-free hemoglobin produced by methods of the present invention may be used in applications requiring physiological oxygen carriers such as in blood substitute solutions, or as in a plasma expander.

Abstract: The enhancement of the antitumor action of tumor necrosis factor by lithium salts is described.

Abstract: A process of preparation of collagen containing in major proportion insoluble collagen is disclosed, including rinsing and washing the collagenic tissue, acidifying the ground material pH value 1 to 4 to get a collagenic paste which is diluted in a diluting solution to get the collagen gel having a concentration in collagen lower than about 2.5 by weight expressed in dry collagen, and performing a shearing stirring at high speed producing ultrasonic effect to get a substantially homogeneous collagenic gel. The collagen has improved mechanical resistance and thermal stability.

Abstract: The invention relates to new monoclonal antibodies which react specifically with human interferon of the IFN-omega type but not with other human interferons, and processes for preparing them, and for methods for their use in the purification and detection of IFN-omega.

Abstract: Lactoferricin (Trade Mark), also called LFCIN (Trade Mark), a potent antimicrobial peptide, is produced by contacting an enzymatic hydrolysate of bovine lactoferrin or any mixture of peptides containing lactoferricin preferably with a butyl moiety-containing hydrophobic interaction chromatography medium, or alternatively with a carboxymethyl moiety-containing cation-exchange chromatography medium, rinsing the medium to remove unbound peptides, desorbing the lactoferricin solution at constant pH, and desalting the desorbed solution. The utility of the process is illustrated, for example, as follows. An enzymatic hydrolysate of bovine lactoferrin (600 g) was contacted with 3000 ml of BUTYL-TOYOPEARL 650M, the medium was rinsed with water, and then with McIlvaine (citric acid-sodium phosphate) buffer at pH 7.0., and lactoferricin was desorbed with McIlvaine buffer at pH 5.0.

Abstract: The present invention provides an intracorporeally injectable non-toxic composition of atelocollagen having an excellent, long-lasting skin swelling effect due to its low viscosity, good fluidity, easy injectability and low antigenicity (without calcification) properties. The composition is prepared by treating an aqueous suspension of atelocollagen with a buffer for physiological conditions. The suspension can have atelocollagen content of 55 to 75 mg/ml, where approximately 20 to 100% by weight of atelocollagen is cross-linked with a polyepoxy compound.

Abstract: A method for treatment of inflammation, comprising the step of administering to a patient in need thereof an effective, inflammation-inhibiting amount of a composition comprising IL-6, or IL-6 and TGF.beta. together in a weight ratio of from about 5:95 to 95:5, preferably from about 20:80 to 80:20. Also disclosed is a composition for treatment of inflammation, comprising as active ingredients IL-6 and TGF.beta. in a weight ratio of from about 5:95 to about 95:5, optionally comprising a carrier in combination with the active ingredients, and a method of reducing migration of neutrophils into tissue of an animal which has received an inflammatory stimulus, comprising the step of administering to the tissue an effective neutrophil-migration-inhibiting amount of a composition as defined above.

Abstract: A method of inhibiting the coloration of human serum albumin expressed by using the gene manipulation technology which method comprises separating coloring contaminants from said human serum albumin before said coloring contaminants bind to the human serum albumin.

Abstract: The present invention relates to a method for isolating and purifying transferrin and lactoferrin receptor proteins from bacterial pathogens by affinity chromatography and to the preparation of vaccine antigens containing the purified receptor proteins.